Oncotarget

Meta-Analysis:

The association between MAD2 and prognosis in cancer: a systematic review and meta-analyses

Tara Byrne, Helen G. Coleman, Janine A. Cooper, W. Glenn McCluggage, Amanda McCann and Fiona Furlong _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102223-102234. https://doi.org/10.18632/oncotarget.18414

Metrics: PDF 735 views  |   HTML 1783 views  |   ?  


Abstract

Tara Byrne1, Helen G. Coleman2, Janine A. Cooper1, W. Glenn McCluggage3, Amanda McCann4,5 and Fiona Furlong1

1School of Pharmacy, Queen’s University Belfast, Belfast, Northern Ireland, UK

2Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK

3Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK

4UCD School of Medicine, College of Health and Agricultural Science, University College Dublin, Dublin, Ireland, UK

5UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, UK

Correspondence to:

Fiona Furlong, email: f.furlong@qub.ac.uk

Keywords: MAD2, cancer, prognosis and systematic review

Received: January 10, 2017     Accepted: May 03, 2017     Published: June 08, 2017

ABSTRACT

This systematic review and meta-analyses investigates the expression of the cell checkpoint regulator, mitotic arrest deficiency protein 2 (MAD2) in cancerous tissue and examines whether an association exists between MAD2 levels and cancer survival and recurrence. Studies investigating MAD2 expression in cancer tissue utilising immunohistochemistry (IHC) were identified by systematic literature searches of Medline, Embase and Web of Science databases by October 2015. Random effects meta-analyses were performed to generate pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of overall and progression-free survival according to MAD2 expression. Forty-three studies were included in the overall review. In 33 studies investigating MAD2 expression by IHC in cancer tissue, a wide range of expression positivity (11–100%) was reported. Higher MAD2 expression was not associated with an increased risk of all-cause mortality in a range of cancers (pooled HR 1.35, 95% CI 0.97–1.87; P = 0.077, n = 15). However, when ovarian cancer studies were removed, a significant pooled HR of 1.59 for risk of all-cause mortality in other cancer patients with higher expressing MAD2 tumours was evident (95% CI, 1.17–2.17; P = 0.003, n = 12). In contrast, higher MAD2 expression was associated with significant decreased risk of all-cause mortality in ovarian cancer patients (pooled HR = 0.50, 95% CI, 0.25–0.97; P = 0.04, n = 3). In conclusion, with the exception of ovarian cancer, increased MAD2 expression is associated with increased risk of all-cause mortality and recurrence in cancer. For ovarian cancer, reduced levels of MAD2 are associated with poorer outcome. Further studies are critical to assess the clinical utility of a MAD2 IHC biomarker.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18414